METHODS	In the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial ( ONTARGET ) , persistent patients ( n = 20,991 ) were compared with individuals who had permanently stopped study medications ( n = 4,629 ) .\